Publication Name	World Journal of Gastroenterology
Manuscript ID	3764
Country	Italy

Received	2013-05-21 11:07
Peer-Review Started	2013-05-21 20:12
First Decision by Editorial Office Director
Return for Revision	2013-07-01 13:33
Revised	2013-08-08 22:41
Publication Fee Transferred
Second Decision by Editor	2013-08-29 07:53
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2013-08-29 09:52
Articles in Press
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-01-10 14:57
Publish the Manuscript Online	2014-02-19 16:57

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Autobiography
Article Title	Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib
Manuscript Source	Invited Manuscript
All Author List	Andrea L Inghilesi, Donatella Gallori, Lorenzo Antonuzzo, Paolo Forte, Daniela Tomcikova, Umberto Arena, Stefano Colagrande, Silvia Pradella, Bernardo Fani, Elena Gianni, Luca Boni, Giacomo Laffi, Francesco Di Costanzo and Fabio Marra
Funding Agency and Grant Number	Funding Agency Grant Number Associazione Italiana per la Ricerca sul Cancro (AIRC) Istituto Toscano Tumori (ITT) to Marra F
Corresponding Author	Fabio Marra, MD, PhD, Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, Largo Brambilla 3, I-50134 Florence, Italy. fabio.marra@unifi.it
Key Words	Hepatocellular carcinoma; Sorafenib; Cirrhosis; Adverse events; Barcelona Clinic Liver Cancer
Core Tip	The study provides information on the clinical characteristics and laboratory findings that predict survival in patients with hepatocellular carcinoma and established cirrhosis treated with sorafenib. This group of patients is particularly fragile and difficult to treat, and therapy with systemic agents, including sorafenib, requires careful monitoring. We report that parameters related to the tumor (extrahepatic spread, vascular invasion), common laboratory tests (alpha-fetoprotein or alkaline phosphatase) and patients characteristics (performance status) are significant predictors of overall survival in this group. These data provide important clinical information for the management of this type of patients.
Publish Date	2014-02-19 16:57
Citation	Inghilesi AL, Gallori D, Antonuzzo L, Forte P, Tomcikova D, Arena U, Colagrande S, Pradella S, Fani B, Gianni E, Boni L, Laffi G, Di Costanzo F, Marra F. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. World J Gastroenterol 2014; 20(3): 786-794
URL	http://www.wjgnet.com/1007-9327/full/v20/i3/786.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i3.786

Full Article (PDF)	WJG-20-786.pdf
Full Article (Word)	WJG-20-786.doc
Manuscript File	3764-Review.docx
Answering Reviewers	3764-Answering reviewers.pdf
Copyright License Agreement	3754-Copyright assignment.doc
Non-Native Speakers of English Editing Certificate	3764-Language certificate.pdf
Peer-review Report	3764-Peer review(s).pdf